True North Therapeutics

True North Therapeutics is a leading biotechnology company that selectively inhibits the complement pathway for diseases with highly unmet clinical needs. The company's leading monoclonal antibody, TNT009, targets the classical complement pathway and selectively inhibits downstream phagocytosis, inflammation, and cytolysis. True North is currently focused on complement-mediated rare diseases in the fields of hematology, nephrology, and neurology. True North was founded in 2013 as a spin-off from iPierian.